Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.01 +0.48 (+0.90%)
Streaming Delayed Price Updated: 11:21 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
34 35 Next >
News headline image
Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Is on Fire Today ↗
Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today. 
Via The Motley Fool
News headline image
Something Happened In Biotech Last Week ↗
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
News headline image
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock ↗
Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets. 
Via The Motley Fool
News headline image
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May ↗
This market-beating biotech stock still has more room to run. 
Via The Motley Fool
News headline image
Is It Too Late to Buy CRISPR Stock? ↗
Five reasons to buy the promising biotech stock now. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Is Marching Higher Today ↗
This gene-editing stock has been heating up over the past week. 
Via The Motley Fool
News headline image
What 14 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
Is CRISPR Therapeutics Stock a Buy Now? ↗
The biotech could soon be a commercial-stage company. 
Via The Motley Fool
News headline image
3 Top Healthcare Stocks to Buy in May ↗
You'll want to hold onto these innovative companies for the long term. 
Via The Motley Fool
News headline image
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers ↗
Cathie Wood is loading up on these biotech stocks. 
Via The Motley Fool
News headline image
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector ↗
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
News headline image
Why CRISPR Therapeutics Just Became an Even Better Buy ↗
Is this a no-brainer investment to add to your portfolio? 
Via The Motley Fool
News headline image
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat ↗
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
News headline image
CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst ↗
 
Via Benzinga
News headline image
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023 ↗
 
Via Benzinga
News headline image
The Best Stocks to Invest $20,000 in Right Now ↗
You'll want to hold on to these top stocks for the long term. 
Via The Motley Fool
News headline image
Buy the Dip: 2 Top Stocks to Snatch Up Now ↗
You don't need to be too gutsy to buy these two stocks while they're down. 
Via The Motley Fool
News headline image
3 Stocks With Huge Catalysts on the Way ↗
Big news could mean big boosts for these stocks. 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Keep Growing for Decades ↗
These businesses will likely only get larger in the future. 
Via The Motley Fool
News headline image
Better Big Biotech Buy: Biogen vs. Vertex ↗
One is slightly cheaper than the other. 
Via The Motley Fool
News headline image
The Top 3 Biotech Stocks to Watch in 2023 ↗
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023. 
Via InvestorPlace
News headline image
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
News headline image
3 High-Growth Biotech Stocks Poised for Success in 2023 ↗
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
News headline image
The Top Healthcare Stocks to Buy With $100 ↗
A small investment now may bring big results over time. 
Via The Motley Fool
News headline image
Why Shares of Editas Medicine Rose Monday ↗
The company is benefiting from positive news affecting other gene-editing stocks. 
Via The Motley Fool
News headline image
Better Growth Stock: Axsome vs. CRISPR Therapeutics ↗
These companies are both in the early days of their growth stories. 
Via The Motley Fool
News headline image
Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock ↗
Shares of CRSP stock are moving higher following an initiation of coverage by Cantor Fitzgerald and continued buys from Cathie Wood. 
Via InvestorPlace
News headline image
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today? ↗
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
News headline image
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis ↗
 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.